Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission

NCT00458523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: alemtuzumab
GENETIC: fluorescence in situ hybridization
GENETIC: mutation analysis
OTHER: flow cytometry

Sponsor

Leeds Cancer Centre at St. James's University Hospital